Diabetes Care, Vol 23, Issue 3 339-344, Copyright © 2000 by American Diabetes Association

ARTICLES

Evaluation of HbA1c determination methods in patients with hemoglobinopathies

WJ Schnedl, R Krause, G Halwachs-Baumann, M Trinker, RW Lipp and GJ Krejs
Department of Internal Medicine, Karl-Franzens University, Graz, Austria. wolfgang.schnedl@kfunigraz.ac.at

OBJECTIVE: To evaluate commercially available determination methods for HbA1c in patients with hemoglobin variants. RESEARCH DESIGN AND METHODS: HbA1c values were determined with various commercially available methods, including ion-exchange high-performance liquid chromatography (HPLC), boronate affinity assay, and immunoagglutination in patients with the hemoglobin mutations Hb Graz, Hb Sherwood Forest, Hb O Padova, Hb D, and Hb S. RESULTS: The effect of hemoglobinopathies on glycohemoglobin measurements was highly method dependent. The HPLC methods for HbA1c determination lacked the resolution necessary to differentiate hemoglobin variants. They demonstrated additional peaks in the chromatograms and HbA1c results either too low or too high compared with the nondiabetic reference range. With all immunoassays, Hb Graz demonstrated falsely low values. The other hemoglobinopathies in our study caused falsely low and/or high HbA1c results in immunoagglutination methods. The boronate affinity method showed values in an acceptable range for all hemoglobin variants. CONCLUSIONS: Because of the local occurrence of Hb variants and the ethnic origin of a given population, every individual laboratory must establish and validate its own assay method. In managing diabetic patients, knowledge of hemoglobinopathies influencing HbA1c determination methods is essential because hemoglobin variants could cause mismanagement of diabetes resulting from false HbA1c determinations.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Smaldone Glycemic Control and Hemoglobinopathy: When A1C May Not Be Reliable Diabetes Spectr, January 1, 2008; 21(1): 46 - 49. [Full Text] [PDF]

				A. Chico, A. Padros, and A. Novials The Korle-Bu Hb Variant in Caucasian Women With Type 1 Diabetes: A pitfall in the assessment of diabetes control Diabetes Care, September 1, 2004; 27(9): 2280 - 2281. [Full Text] [PDF]

				D. E. Goldstein, R. R. Little, R. A. Lorenz, J. I. Malone, D. Nathan, C. M. Peterson, and D. B. Sacks Tests of Glycemia in Diabetes Diabetes Care, July 1, 2004; 27(7): 1761 - 1773. [Full Text] [PDF]

				J L Camargo and J L Gross Conditions associated with very low values of glycohaemoglobin measured by an HPLC method J. Clin. Pathol., April 1, 2004; 57(4): 346 - 349. [Abstract] [Full Text] [PDF]

				T Lahousen, R E Roller, R W Lipp, and W J Schnedl Silent haemoglobin variants and determination of HbA1c with the HPLC Bio-Rad Variant II J. Clin. Pathol., September 1, 2002; 55(9): 699 - 703. [Abstract] [Full Text] [PDF]

				R G. Barr, D. M. Nathan, J. B. Meigs, and D. E. Singer Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus Ann Intern Med, August 20, 2002; 137(4): 263 - 272. [Abstract] [Full Text] [PDF]

				D. B. Sacks, D. E. Bruns, D. E. Goldstein, N. K. Maclaren, J. M. McDonald, and M. Parrott Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus Clin. Chem., March 1, 2002; 48(3): 436 - 472. [Abstract] [Full Text] [PDF]

				L. Bry, P. C. Chen, and D. B. Sacks Effects of Hemoglobin Variants and Chemically Modified Derivatives on Assays for Glycohemoglobin Clin. Chem., February 1, 2001; 47(2): 153 - 163. [Abstract] [Full Text] [PDF]